Ezjr Inc – ‘10-12G’ on 10/15/09

On:  Thursday, 10/15/09, at 2:54pm ET   ·   Accession #:  1350071-9-221   ·   File #:  0-51861

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Registration of Securities (General Form)   —   Form 10
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-12G      Registration of Securities (General Form)             48    179K 
 2: EX-23.1     Consent of Auditor                                     1      6K 

10-12G   —   Registration of Securities (General Form)
Document Table of Contents

10-12G
1st Page of 48
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
U.S. SECURITIES AND EXCHANGE COMMISSION 
  Washington, D.C. 20549

FORM 10 

GENERAL FORM FOR REGISTRATION OF SECURITIES   

Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934     

EZJR, Inc.  
------------------------------------------------------
(Exact name of registrant as specified in its charter)

Nevada                          20-0667864    
----------------------------------    ----------------------        
(State or other jurisdiction of        (I.R.S. Employer             
incorporation or organization)        Identification No.)         

3415 Ocatillo Mesa Way, North Las Vegas, NV  89031    
-----------------------------------------------------   
(Address of principal executive offices)(Zip Code)    
Issuer's telephone number, including area code: (702) 631-4251

Copies to:  
Thomas C. Cook, Esq.  
500 N. Rainbow, Suite 300   
Las Vegas, NV  89107  
Telephone Number: (702) 221-1925  
Facsimile Number: (702) 221-1963  

Securities to be registered under Section 12(b) of the Act:  None     
-----------------------------------------------------------------     

Securities to be registered under section 12(g) of the Act:                     

Title of Each Class               Name on each exchange on which      
to be registered                  each class is to be registered      
---------------------             ------------------------------      
Common Stock, $0.0001             OTC-Bulletin Board                  

Indicate by checkmark whether the registrant is a large accelerated filer, an   
accelerated filer, a non-accelerated filer, or a smaller reporting company. See 
the definitions of "large accelerated filer," "accelerated filer," and "smaller 
reporting company" in Rule 12b-2 of the Exchange Act.                           

[ ] Large accelerated filer      [ ] Accelerated filer        
[ ] Non-accelerated filer        [X] Smaller reporting company

  EXPLANATORY NOTE

We are filing this General Form for Registration of Securities on Form 10 to    
register our common stock, par value $0.0001 per share (the "Common Stock"),    
pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended    
(the "Exchange Act").                                                           

Once this registration statement is deemed effective, we will be subject to     
the requirements of Regulation 13A under the Exchange Act, which will require   
us to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and     
current reports on Form 8-K, and we will be required to comply with all other   
obligations of the Exchange Act applicable to issuers filing registration       
statements pursuant to Section 12(g) of the Exchange Act.                       

Unless otherwise noted, references in this registration statement to the        
"Registrant," the "Company," "we," "our" or "us" means EZJR, Inc.  Our          
principal place of business is located at 3415 Ocatillo Mesa Way, North Las     
Vegas, NV  89031.  Our telephone number is (702) 631-4251.                      

10-12G
2nd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 2nd
TABLE OF CONTENTS 

                                                                          PAGE
                                                                          ----
ITEM 1. BUSINESS..............................................................3 

ITEM 1A. RISK FACTORS.........................................................9 

ITEM 2. FINANCIAL INFORMATION................................................22 

ITEM 3. PROPERTIES...........................................................23 

ITEM 4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.......23 

ITEM 5. DIRECTORS AND EXECUTIVE OFFICERS.....................................25 

ITEM 6. EXECUTIVE COMPENSATION...............................................26 

ITEM 7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,                         
       AND DIRECTOR INDEPENDENCE............................................27

ITEM 8. LEGAL PROCEEDINGS....................................................27 

ITEM 9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S                       
       COMMON EQUITY AND RELATED STOCKHOLDER MATTERS                        28

ITEM 10. RECENT SALES OF UNREGISTERED SECURITIES.............................29 

ITEM 11. DESCRIPTION OF REGISTRANT'S SECURITIES TO BE REGISTERED.............29 

ITEM 12. INDEMNIFICATION OF DIRECTORS AND OFFICERS...........................30 

ITEM 13. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.........................30 

ITEM 14. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING            
        AND FINANCIAL DISCLOSURE............................................31

ITEM 15. FINANCIAL STATEMENTS AND EXHIBITS...................................31 

SIGNATURES...................................................................32 

 2

10-12G
3rd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 3rd
  FORWARD LOOKING STATEMENTS

There are statements in this registration statement that are not historical     
facts. These "forward-looking statements" can be identified by use of           
terminology such as "believe," "hope," "may," "anticipate," "should,"           
"intend," "plan," "will," "expect," "estimate," "project," "positioned,"        
"strategy" and similar expressions. You should be aware that these              
forward-looking statements are subject to risks and uncertainties that are      
beyond our control.  For a discussion of these risks, you should read this      
entire Registration Statement carefully, especially the risks discussed under   
the section entitled "Risk Factors."  Although management believes that the     
assumptions underlying the forward looking statements included in this          
Registration Statement are reasonable, they do not guarantee our future         
performance, and actual results could differ from those contemplated by these   
forward looking statements. The assumptions used for purposes of the forward-   
looking statements specified in the following information represent estimates   
of future events and are subject to uncertainty as to possible changes in       
economic, legislative, industry, and other circumstances.  As a result, the     
identification and interpretation of data and other information and their use   
in developing and selecting assumptions from and among reasonable               
alternatives require the exercise of judgment. To the extent that the assumed   
events do not occur, the outcome may vary substantially from anticipated or     
projected results, and, accordingly, no opinion is expressed on the             
achievability of those forward-looking statements.  In light of these risks     
and uncertainties, there can be no assurance that the results and events        
contemplated by the forward-looking statements contained in this Registration   
Statement will in fact transpire. You are cautioned to not place undue          
reliance on these forward-looking statements, which speak only as of their      
dates.  We do not undertake any obligation to update or revise any forward-     
looking statements.                                                             

Item 1. Business.                                                               

Business History                                                                

EZJR, Inc, ("we", "us", "our", the "Company" or the "Registrant") was           
organized August 14, 2006 (Date of Inception) under the laws of the State of    
Nevada, as IVPSA Corporation ("IVP").  The Company was incorporated as a        
subsidiary of Eaton Laboratories, Inc., a Nevada corporation.  The Company is   
a developmental medical device company which plans to produce medical           
devices, utilizing the outside contract manufacturing facilities.               

On July 25, 2008, EZJR, Inc., a Nevada corporation and IVPSA Corporation,       
entered into an Acquisition Agreement and Plan of Merger whereby IVP acquired   
all the outstanding shares of common stock of EZJR from its sole stockholder    
in an exchange for $4,000 cash in a transaction where IVP is the successor      
corporation.  Upon the merger of the two entities, IVP changed its corporate    
name to EZJR, Inc.                                                              

 3

10-12G
4th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 4th
Business of Issuer                                                              

EZJR, Inc. is a development stage medical device company which plans to         
produce medical devices, utilizing the services contract manufacturing          
facilities.  EZJR does not have the resources to conduct any required           
clinical trails to obtain FDA approval.  Therefore, EZJR plans to outsource     
this task to third parties who have the facilities to conduct any required      
clinical trials.  EZJR also plans to subcontract the manufacturing and          
production process of any future medical device to a FDA approved contract      
manufacturing facility which can produce sterile medical devices under Good     
Manufacturing Practices.  The company plans to distribute its product(s) into   
the marketplace through medical supply wholesalers, hospitals and health        
maintenance organizations.                                                      

Exclusive Option Agreement                                                      
--------------------------                                                      

EZJR entered into an "Exclusive Option Agreement" with the Cleveland Clinic,    
Cleveland, Ohio, on March 15, 2007 to investigate and conduct due diligence     
with respect to the commercial viability of the licensable technology prior to  
executing a formal License Agreement.  The technology consists of a central     
line catheter with the ability to access the jugular bulb.  The jugular bulb    
is part of the internal jugular vein that collects the blood from the brain,    
from the superficial parts of the face, and from the neck.  This catheter was   
invented by a physician at the Cleveland Clinic.  The Company paid the          
Cleveland Clinic, a nonrefundable fee of $46,000 for this exclusive option      
agreement.  The agreement terminated in March, 2009.  EZJR has not renewed      
this option agreement or entered into any licensing agreement with the          
Cleveland Clinic.  EZJR has been unable to find a contract manufacturer who     
can handle the technical design of this proposed catheter.                      

Central line catheter product                                                   
-----------------------------                                                   

Most patients in the neuro critical care setting as well as patients            
undergoing neurovascular procedures receive a central line catheter.  Jugular   
bulb oxygen saturation monitoring is a well established method used in          
neurosurgical intensive care, particularly in context of head injury.           
Jugular Bulb Saturation measures the efficiency of oxygen use by the brain.     

Currently, catheters for measuring jugular venous oxygen saturation are         
inserted into the jugular vein in a cephalad (toward the head) direction, with  
an catheter accessing the jugular bulb.  The cephalad method is complex,        
time-consuming and could lead to complications.  Traditionally,                 
anesthesiologists and critical care physicians use caudad (toward the feet)     
catheter insertion to access the central venous system.  The fear of            
complications with introducing a catheter towards the brain has discouraged     
the clinicians in using this monitoring method.                                 

 4

10-12G
5th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 5th
A potential benefit that might be achieved after the development of this        
catheter will provide anesthesiologists a method for double catheterization     
(inserting both caudad and cephalad catheters) all within one catheter.  In     
other words, this design provides for one catheter to monitor a patient's       
vital signs, as compared to using two catheters for the same meansurements.     

This proposed catheter will give access to the blood exiting the brain,         
which can help the anesthesiologist monitor brain metabolism and its            
byproducts.  Such information is important to neuro-critical care units and     
intracranial vascular surgical procedures.  This method has also been           
suggested for monitoring the brain in cardiac surgical procedures.              

Prototype Development                                                           
---------------------                                                           

EZJR has yet to find a contract manufacturer who can build a working            
prototype of this catheter.  In order to continue with this project, EZJR       
needs a working prototype that can be readily duplicated by a contract          
manufacturer at a reasonable price.  In November, 2007, EZJR signed a           
purchase order with Interplex Medical LLC of Midford, OH, to help the Company   
develop this working prototype.  The terms of the purchase order require that   
EZJR pays up to $25,000 for the development of a prototype catheter.  Their     
engineers were unable to successfully build this prototype.  If a working       
prototype cannot be built, there would be no reason to proceed in attempting    
to bring this medical device to the market.                                     

The difficulty in building a double catheterization prototype of this catheter  
rests in its design.  It is a catheter within a catheter.  The catheter inside  
the larger catheter must make a 180 degree turn without crimping its opening    
to server its purpose.  In other words, blood must be able to pass within the   
inner catheter without any blockage, after the inner catheter has made a 180    
turn.  We have been unable to produce a working catheter which successfully     
meets these design specifications.                                              

 5

10-12G
6th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 6th
Existing or Probable Government Regulations                                     
-------------------------------------------                                     

An investigational device exemption ("IDE") allows the investigational device   
to be used in a clinical study in order to collect safety and effectiveness     
data required to support a Premarket Approval ("PMA") application or a          
Premarket Notification submission to Food and Drug Administration ("FDA").      
Clinical studies are most often conducted to support a PMA.  Investigational    
use also includes clinical evaluation of certain modifications or new           
intended uses of legally marketed devices.  All clinical evaluations of         
investigational devices, unless exempt, must have an approved IDE before the    
study is initiated.  Clinical evaluation of devices that have not been          
cleared for marketing requires:                                                 

  o   an IDE approved by an institutional review board (IRB). If the study
      involves a significant risk device, the IDE must also be approved by
FDA;                                                          

o  informed consent from all patients;                                

o  labeling for investigational use only                              

o  monitoring of the study and;                                       

o  required records and reports.                                      

In order to conduct a significant risk device study, EZJR must:                 

o  submit a complete IDE application to FDA for review and obtain FDA 
approval of the IDE;                                            

o  submit the investigational plan and report of prior investigations 
   and to the IRB at each institution where the investigation is to be
conducted for review and approval; and                          

o  select qualified investigators, provide them with all necessary    
information on the investigational plan and report of prior     
    investigations, and obtain signed investigator agreements from them.

 6

10-12G
7th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 7th
Once an IDE application is approved, the following requirements must be met     
in order to conduct the investigation in compliance with the IDE regulation:    

  o  Labeling - The device must be labeled in accordance with the labeling
     provisions of the IDE regulation and must bear the statement "CAUTION
    Investigational Device. Limited by Federal (or United States) law to
investigational use."                                           

o  Distribution - Investigational devices can only be distributed to  
qualified investigators.                                        

o  Informed Consent - Each subject must be provided with and sign an  
informed consent form before being enrolled in the study.       

  o  Monitoring - All investigations must be properly monitored to protect
 the human subjects and assure compliance with approved protocols.

o  Commercialization, promotion, and misrepresentation of an          
    investigational device and prolongation of the study are prohibited.

o  Records and Reports - Sponsors and investigators are required to   
   maintain specified records and make reports to investigators, IRBs,
and FDA.                                                        

EZJR Funding Requirements                                                       
-------------------------                                                       

EZJR does not have the required capital or funding to complete this initial     
project.  Management anticipates EZJR will require at least $500,000 to         
complete to perform the required FDA studies and produce inventory.  The        
Company has yet to source this funding.                                         

The Company has been seeking funding from a number of sources, but has yet      
to secure any funding, especially during this current economic downturn.        
Management continues to seek different funding sources in order to initiate     
its business plan.  The downturn in the economy has limited our sources of      
financing.  Management continues to seek financing with no success.  If the     
Company is unable to obtain capital to finance its plan of operations or        
identify alternative capital, it may need to curtail, limit or cease our        
existing operations.                                                            

Future funding could result in potentially dilutive issuances of equity         
securities, the incurrence of debt, contingent liabilities and/or               
amortization of expenses related to goodwill and other intangible assets, which 
could materially adversely affect the Company's business, results of            
operations and financial condition.  Any future acquisitions of other           
businesses, technologies, services or product(s) might require the Company to   
obtain additional equity or debt financing, which might not be available on     
terms favorable to the Company, or at all, and such financing, if available,    
might be dilutive.                                                              

7   

10-12G
8th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 8th
Competition                                                                     
-----------                                                                     

The medical device industry is highly competitive.  Factors contributing to     
the industry's increasingly competitive market include regulatory changes,      
product substitution, technological advances, and the entrance of new           
competitors.                                                                    

Most all of EZJR's competitors have significantly greater financial,            
marketing, other resources, and larger customer bases than EZJR has and are     
more financially leveraged.  As a result, these competitors may be able to      
adapt changes in customer requirements more quickly; introduce new and more     
innovative products more quickly; better adapt to downturns in the economy or   
other decreases in sales; better withstand pressure for cancelled services,     
take advantage of acquisition and other opportunities more readily; devote      
greater resources to the marketing and sale of their products; and adapt more   
aggressive pricing policies.  All of which may contribute to intensifying       
competition and may affect EZJR's future revenue growth.                        

Patent, Trademark, License and Franchise Restrictions and Contractual           
Obligations and Concessions                                                     
---------------------------------------------------------------------           

We currently have no pending or provisional patents or trademark                
applications.                                                                   

Research and Development Activities and Costs                                   
---------------------------------------------                                   

The majority of EZJR expenses involved the costs related to the research and    
development of the central line catheter.  These costs included entering into   
two option contracts ($46,000), with the Cleveland Clinic, and paying for       
catheter development costs (approximately $17,000).                             

Compliance With Environmental Laws                                              
----------------------------------                                              

We are not aware of any environmental laws that have been enacted, nor are we   
aware of any such laws being contemplated for the future, that impact issues    
specific to our business. In our industry, environmental laws are anticipated   
to apply directly to the owners and operators of companies. They do not apply   
to companies or individuals providing consulting services, unless they have     
been engaged to consult on environmental matters. We are not planning to        
provide environmental consulting services.                                      

 8

10-12G
9th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 9th
Employees                                                                       
---------                                                                       

We have no employees at the present time.  Our sole officer and director        
is responsible for all planning, developing and operational duties and          
will continue to do so throughout the early stages of our growth.               

He devotes 5-10 hours per week of his time to EZJR's business.  All             
functions including development, strategy, negotiations and clerical work is    
being provided by the sole officer/director on a voluntary basis, without       
compensation.                                                                   

We have no intention of hiring employees until the business has been            
successfully launched and we have sufficient, reliable revenue from our         
operations.  Our officer and director is planning to do whatever work is        
required until our business to the point of having positive cash flow.  We do   
not expect to hire any employees during through 2010.                           

Item 1A. Risk Factors.                                                          

An investment in the Company is highly speculative in nature and involves a     
high degree of risk.                                                            

1.  SINCE EZJR IS A DEVELOPMENT STAGE MEDICAL DEVICE COMPANY, EZJR HAS          
GENERATED NO REVENUES, AND THERE ARE NO ASSURANCES THAT ITS BUSINESS PLAN       
WILL BE SUCCESSFUL.                                                             

EZJR expects to incur operating losses in future periods as EZJR incurs         
significant expenses associated with the initial startup of its business.       
Further, there are no assurances that EZJR will be successful in realizing      
revenues or in achieving or sustaining positive cash flow at any time in the    
future.  Any such failure could result in the possible closure of EZJR's        
business or force the Company to seek additional capital through loans or       
additional sales of the Company's equity securities to continue business        
operations, which would dilute the value of any shares owned by the Company's   
shareholders.                                                                   

2.  IF EZJR'S BUSINESS PLAN IS NOT SUCCESSFUL, EZJR MAY NOT BE ABLE TO          
CONTINUE OPERATIONS AS A GOING CONCERN AND ITS STOCKHOLDERS MAY LOSE THEIR      
ENTIRE INVESTMENT IN EZJR.                                                      

As discussed in the Notes to the Financial Statements included in this          
Current Report, at June 30, 2009, EZJR had a working capital deficit of         
$(480).  EZJR had a net loss of approximately $(78,381) from its inception      
to June 30, 2009.                                                               

 9

10-12G
10th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 10th
These factors raise substantial doubt that EZJR will be able to continue        
operations as a going concern, and EZJR's independent auditors included an      
explanatory paragraph regarding this uncertainty in their report on the         
financial statements for the period from inception to June 30, 2009.  EZJR's    
ability to continue as a going concern is dependent upon generating cash flow   
sufficient to fund operations and reducing operating expenses.  EZJR's          
business plan may not be successful in addressing these issues.  If EZJR        
cannot continue as a going concern, its stockholders may lose their entire      
investment in EZJR.                                                             

3.  EZJR EXPECTS LOSSES IN THE FUTURE BECAUSE EZJR HAS NO REVENUE.              

EZJR has generated no revenues, management expects losses over the next         
twelve (12) months since there are no revenues to offset the expenses           
associated in executing EZJR's business plan.  EZJR cannot guarantee that it    
will ever be successful in generating revenues in the future.  EZJR             
recognizes that if the Company is unable to generate revenues, it will not be   
able to earn profits or continue operations as a going concern.  There is no    
history upon which to base any assumption as to the likelihood that the         
Company will prove successful, and EZJR can provide selling shareholders with   
no assurance that it will generate any operating revenues or ever achieve       
profitable operations.                                                          

4. SINCE EZJR'S OFFICER DOES NOT DEVOTE HIS FULL TIME TO THE COMPANY, HIS       
OTHER ACTIVITIES COULD SLOW DOWN EZJR'S OPERATIONS.                             

T J Jesky, the sole officer of EZJR does not devote all of his time to the      
Company's operations.  He is semi-retired and devotes his time to his family    
and personal activities.   Therefore, it is possible that a conflict of         
interest with regard to his time may arise based on his involvement in other    
activities.  His other activities will prevent him from devoting full-time to   
EZJR's operations which could slow EZJR's operations and may reduce its         
financial results because of the slow down in operations.                       

The President and Director of the company, currently devotes approximately 5-   
10 hours per week to company matters.  The responsibility of developing the     
company's business, and fulfilling the reporting requirements of a public       
company all fall upon Mr. Jesky.  Mr. Jesky was the former President of Eaton   
Laboratories, the Company that spun off IVPSA Corporation.  EZJR has not        
formulated a plan to resolve any possible conflict of interest with his other   
business activities.  Mr. Jesky intends to limit his role in his other          
activities and devote more of his time to EZJR after the Company attains a      
sufficient level of revenue and is able to provide sufficient officers'         
salaries per its business plan.  In the event he is unable to fulfill any       
aspect of his duties to the company, EZJR may experience a shortfall or         
complete lack of sales resulting in little or no profits and eventual closure   
of the business.                                                                

  10

10-12G
11th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 11th
5.  EZJR'S SOLE OFFICER, MR. T J JESKY, HAS NO PRIOR EXPERIENCE IN RUNNING A    
MEDICAL DEVICE COMPANY.                                                         

EZJR's sole executive officer has no experience in operating a medical          
device company.  Mr. Jesky did serve as President of Eaton Laboratories from    
February 2, 2000 (inception) until March 2007.  Due to his lack of experience   
in running a medical device company, the executive officer may make wrong       
decisions and choices regarding key decisions on behalf of the Company.         
Consequently, EZJR may suffer irreparable harm due to management's lack of      
experience in this industry.                                                    

6.  IF EZJR IS UNABLE TO OBTAIN ADDITIONAL FUNDING, ITS BUSINESS OPERATIONS     
WILL BE HARMED.  EVEN IF EZJR DOES OBTAIN ADDITIONAL FINANCING ITS THEN         
EXISTING SHAREHOLDERS MAY SUFFER SUBSTANTIAL DILUTION.                          

As of June 30, 2009, EZJR had no working cash nor equivalents.  EZJR needs      
at least five hundred thousand dollars ($500,000) in order to obtain FDA        
(Food and Drug Administration) approval to market its potential medical         
device.  EZJR determined that $500,000 is needed for:  1) engineering design    
and specifications of the medical device; 2) production of the medical          
device; 3) FDA application process; 4) conducting the necessary FDA studies;    
and 5) producing a working inventory of the medical device.                     

The company has yet to find sourcing for this endeavor.  The Company has        
initial plans to develop a catheter medical device.  The regulatory             
requirements of the FDA will be capital intensive, this project will also       
require a larger working capital basis to maintain adequate inventories of      
the approved product.  This need for additional funds will be derived from      
future stock offerings.  These future offerings could significantly dilute      
the value of any previous investor's investment.  If and when FDA approval      
can be obtained for this product, the Company will be required to produce       
product for distribution.  The company anticipates that its budge for           
$500,000 will include retail inventory of the medical device.                   

There are no guarantees given that the Company will be able to find the         
necessary financing or the necessary financing will be available, if required   
or if available, will be on terms and conditions satisfactory to management.    
The above outlined capital problems which could significantly affect the        
value of any Common Shares and could result in the loss of an investor's        
entire investment.                                                              

  11

10-12G
12th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 12th
7.  EZJR MAY NOT BE ABLE TO RAISE SUFFICIENT CAPITAL OR GENERATE ADEQUATE       
REVENUE TO MEET ITS OBLIGATIONS AND FUND ITS OPERATING EXPENSES.                

Failure to raise adequate capital and generate adequate sales revenues to       
meet EZJR's obligations and develop and sustain its operations could result     
in reducing or ceasing EZJR's operations.  Additionally, even if EZJR does      
raise sufficient capital and generate revenues to support its operating         
expenses, there can be no assurances that the revenue will be sufficient to     
enable EZJR to develop business to a level where it will generate profits and   
cash flows from operations.  These matters raise substantial doubt about        
EZJR's ability to continue as a going concern.  EZJR's independent auditors     
currently included an explanatory paragraph in their report on the financial    
statements regarding concerns about EZJR's ability to continue as a going       
concern.                                                                        

8.  EZJR MAY NOT BE ABLE TO COMPETE WITH LARGER MEDICAL DEVICE COMPANIES, THE   
MAJORITY OF WHOM HAVE GREATER RESOURCES AND EXPERIENCE THAN EZJR DOES.          

The Company has no way of knowing that other companies may be working on        
bringing the same medical device into the market.  In order to obtain FDA       
approval to market a medical device, it can take from twelve (12) to            
eighteen (18) months to obtain approval from the FDA.  And, there is no way     
to know if someone else has submitted similar paperwork beforehand.             
Therefore, there is always a possibility that similar medical device may        
enter the market before EZJR's licensed product.                                

Many of the Company's competitors are significantly larger and have             
substantially greater financial, distribution, marketing and other resources    
and have achieved better recognition for their brand names for product lines    
or certain products than the Company.  There is no assurance that the Company   
will be able to compete successfully against present or future competitors or   
that competitive pressures faced by the Company will not have a material        
adverse effect on the Company.                                                  

9.  IF EZJR RECEIVES REGULATORY APPROVAL EZJR WILL ALSO BE SUBJECT TO ONGOING   
FDA OBLIGATION AND CONTINUED REGULATORY REVIEW.                                 

Any regulatory approvals that EZJR receives for its products may also be        
subject to limitations on the indicated uses for which the product may be       
marketed or contain requirements for potentially costly post-marketing          
follow-up studies. In addition EZJR or its third party manufacturers may be     
required to undergo a pre-approval inspection of manufacturing facilities by    
the FDA and foreign authorities before obtaining marketing approval and will    
be subject to periodic inspection by the FDA and corresponding foreign          
regulatory authorities under reciprocal agreements with the FDA.  Such          
inspections may result in compliance issues that could prevent or delay         
marketing approval or require the expenditure of money or other resources to    
correct noncompliance.                                                          

12

10-12G
13th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 13th
If a regulatory agency discovers previously unknown problems with a product,    
such as adverse events of unanticipated severity or frequency, or problems      
with the facility where the product is manufactured, a regulatory agency may    
impose restrictions on that product, EZJR's collaborators, or EZJR, including   
requiring withdrawal of the product from the market.  EZJR's product            
candidates will also be subject to ongoing FDA requirements for the labeling,   
packaging, storage, advertising, promotion, record-keeping, and submission of   
safety and other post-market information on the drug.  If EZJR's product        
candidates fail to comply with applicable regulatory requirements, a            
regulatory agency may:                                                          

o    issue warning letters;                                           
o    impose civil or criminal penalties;                              
o    withdraw regulatory approval;                                    
o    suspend any ongoing clinical trials;                             
o    refuse to approve pending applications or supplements to approved
applications filed by EZJR or EZJR's collaborators;         
o    impose restrictions on operations, including costly new          
manufacturing requirements; or                              
o    seize or detain products or require a product recall.            

If EZJR fails to comply with applicable domestic regulatory requirements,       
EZJR may be subject to fines, suspension or withdrawal of regulatory            
approvals, product recalls, seizure of products, operating restrictions, and    
criminal prosecution.                                                           

10.  EZJR FACES THE RISK OF NOT BEING ABLE TO COMPLY WITH EACH OF THE STEPS     
IN THE FDA PRE-MARKETING APPROVAL PROCESS.                                      

If EZJR is successful in raising the required funds to develop its first        
medical device, there are no assurances that the Company can comply with the    
required steps in the FDA pre-marketing approval process.  This includes        
compiling studies accepted by FDA to their satisfaction.  Failure to do so,     
would result in compiling new studies at an added expense to the Company.       
The Company may not have the required funds to repeat FDA compliance studies.   
This would mean EZJR would either need to seek more funding or close its        
business operations.                                                            

  13

10-12G
14th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 14th
11.  THE FDA APPROVAL PROCESS CAN BE VERY LENGTHY AND UNCERTAIN                 

Upon the completion of the required testing, analysis of the testing, and       
producing an actual manufacturing lot of the product, the Company will be       
ready to submit an Application to the FDA for their review and comment.  EZJR   
expects this process could take eleven months after EZJR obtains funding,       
just to produce the required data for a Submission Application.  Once the       
Application is received by the FDA, they have 180 days to respond to an         
Application.  At that time, based on the data provide, they will most likely    
comment on the Application in that they will require clarification or more      
data.  The Company expects the FDA approval process to last between 10-12       
months.  If the FDA requires additional data following the review of EZJR's     
Application, this will require additional expense and loss of time to bring     
its product to the market.  There exists an uncertainty on how long the         
actual FDA approval process will taken, as they may require additional          
information.  This uncertainty can adversely effect when EZJR can bring the     
final product to the marketplace.                                               

12.  TO BE SUCCESSFUL, MEDICAL DEVICE(S) MUST BE ACCEPTED BY HEALTH CARE        
PROFESSIONALS, WHO CAN BE VERY SLOW TO ADOPT OR UNRECEPTIVE TO NEW              
TECHNOLOGIES AND PRODUCTS.                                                      

EZJR's future medical devices, if approved for marketing, may not achieve       
market acceptance since hospitals, physicians, patients or the medical          
community in general may decide to not accept and utilize these products.       
The product candidates that EZJR is attempting to develop represent             
substantial departures from established treatment methods and will compete      
with a number of more conventional drugs and therapies manufactured and         
marketed by major medical device companies.  The degree of market acceptance    
of any of our developed products will depend on a number of factors,            
including:                                                                      

  o    the establishment and demonstration to the medical community of the
clinical efficacy and safety of EZJR's product candidates;  

o    the ability to create products that are superior to alternatives 
currently on the market, including in terms of pricing and  
cost-effectiveness, relative convenience, and ease of       
administration;                                             

o    the prevalence and severity of adverse side effects; and         

o    the ability to establish in the medical community the potential  
advantage of EZJR's medical device over alternative medical 
devices.                                                    

If the health care community does not accept EZJR's products for any of the     
foregoing reasons, EZJR's revenues from the sale of any approved product        
would be significantly reduced.                                                 

  14

10-12G
15th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 15th
13.  IF EZJR IS UNABLE TO OBTAIN AND MAINTAIN PATENT AND OTHER INTELLECTUAL     
PROPERTY OWNERSHIP RIGHTS RELATING TO THE DEVELOPMENT MEDICAL DEVICES, THEN     
THE COMPANY MAY NOT BE ABLE TO SELL ANY MEDICAL DEVICES, WHICH WOULD HAVE A     
MATERIAL ADVERSE IMPACT ON EZJR'S RESULTS OF OPERATIONS AND THE PRICE OF THE    
COMPANY'S COMMON STOCK.                                                         

EZJR currently does not own any right, title or interest in any patent          
application for any medical device.  If in the future EZJR does file a patent   
application, there are no assurances that it will not be successfully           
challenged or circumvented by competitors or others.  EZJR has no assurance     
that the United States Patent and Trademark Office will issue the Patent or     
that the scope of any claims granted in an issued patent will provide broad     
protection or a competitive advantage to us.  If the Patent fails to issue in   
sufficient scope or at all, or if the patent issues but EZJR fails to           
maintain and enforce EZJR's rights in the issued patent, or if EZJR fails to    
maintain and protect its rights in other intellectual property, including       
know-how, trade secrets and trademarks, such failures, individually and in      
the aggregate, could have a material adverse effect upon EZJR's business        
prospects, financial condition and results of operations.  If such patents      
issue, they will be presumed valid, but there is no assurance that they will    
not be successfully challenged or circumvented by competitors or others.        

EZJR also relies upon trade secrets and other unpatented proprietary            
technology.  No assurance can be given that the Company can meaningfully        
protect its rights with regard to such unpatented proprietary technology or     
that competitors will not duplicate or independently develop substantially      
equivalent technology.                                                          

14.  THE REIMBURSEMENT STATUS OF NEWLY APPROVED HEALTHCARE PRODUCTS AND         
TREATMENTS IS NO ESTABLISHED AND FAILURE TO OBTAIN ADEQUATE REIMBURSEMENT       
COULD LIMIT EZJR'S ABILITY TO MARKET ANY PRODUCTS THE COMPANY MAY DEVELOP.      

EZJR's ability to commercialize its product candidates in domestic markets      
successfully will depend in part on the extent to which governmental            
authorities, private health insurers, managed care programs, and other          
organizations establish appropriate coverage and reimbursement levels for the   
cost of EZJR's products and related treatments.  There is significant           
uncertainty related to the reimbursement of newly approved medical devices.     
Third party payors are increasingly attempting to contain healthcare costs      
and challenging the prices charged for medical products and services, both by   
limiting coverage and by reducing the level of reimbursement for medical        
devices.  For example, the trend toward managed health care in the United       
States, which could significantly influence the purchase of health care         
services and products, as well as legislative proposals to reform health care   
or reduce government insurance programs, may result in lower prices for the     
product candidates or exclusion of any product candidates from coverage and     
reimbursement programs.  If third parties fail to provide adequate              
reimbursement for EZJR's products, consumers and health care providers may      
choose not to use EZJR's products, which could significantly reduce EZJR's      
revenues from the sale of any approved product and prevent EZJR from            
realizing an acceptable return on the Company's investment in product           
development.                                                                    

  15

10-12G
16th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 16th
15.  EZJR HAS NO COMMERCIAL PRODUCTION CAPABILITY AND EZJR MAY ENCOUNTER        
PRODUCTION PROBLEMS OR DELAYS, WHICH COULD RESULT IN LOWER REVENUES.            

To date, EZJR has not produced any products.  To achieve anticipated customer   
demand levels EZJR will need to find suppliers who can contract manufacturer    
the products for the Company and provide the Company with adequate levels of    
inventory.  EZJR's contract manufacturers may not be able to maintain           
acceptable quality standards.  If EZJR cannot achieve the required level and    
quality of production, the Company may need to outsource production or rely     
on licensing and other arrangements with third parties.  EZJR may not be able   
to successfully outsource its production or enter into licensing or other       
arrangements under acceptable terms with these third parties, which could       
adversely affect its business.  EZJR's inability to identify potential          
manufacturers, or to enter into or maintain agreements with them on             
acceptable terms, could delay or prevent the commercialization of its           
products, which would adversely affect its ability to generate revenues and     
could prevent the Company from achieving or maintaining profitability.  In      
addition reliance on third-party manufacturers could reduce EZJR's gross        
margins and expose the Company to the risks inherent in relying on others.      
EZJR may also encounter problems with production yields, shortages of           
qualified personnel, production costs, and the development of advanced          
manufacturing techniques and process controls.                                  

16.  EZJR WILL BE REQUIRED TO COMPLY WITH GOOD MANUFACTURING REQUIREMENTS,      
AND ITS FAILURE TO DO SO MAY SUBJECT THE COMPANY TO FINES AND OTHER             
PENALTIES.                                                                      

EZJR, or its other third party manufacturers of its products must comply with   
current good manufacturing practice, or cGMP, requirements demanded by          
customers and enforced by the FDA through its facilities inspection program.    

These requirements include quality control, quality assurance, and the          
maintenance of records and documentation.  EZJR, its collaborators, or other    
third party manufacturers of EZJR's products may be unable to comply with       
these cGMP requirements and with other FDA, state, and foreign regulatory       
requirements.  These requirements may change over time and EZJR, or third       
party manufacturers, may be unable to comply with the revised requirements.     
A failure to comply with these requirements may result in fines and civil       
penalties, suspension of production, suspension or delay in product approval,   
product seizure or recall, or withdrawal of product approval. If the safety     
of any quantities supplied by third-parties is compromised due to their         
failure to adhere to applicable laws or for other reasons, EZJR may not be      
able to obtain regulatory approval for, or successfully commercialize,          
product candidates that the Company may develop.                                

  16

10-12G
17th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 17th
17.  EZJR MAY INCUR SUBSTANTIAL LIABILITIES FROM ANY PRODUCT LIABILITY          
CLAIMS, INCLUDING CLAIMS MADE AGAINST THIRD PARTIES EZJR HAS AGREED TO          
INDEMNIFY.                                                                      

EZJR faces an inherent risk of product liability exposure related to the        
testing of its product candidates in human clinical trials, and will face an    
even greater risk if the Company sells its product candidates commercially.     
An individual may bring a liability claim against the Company if one of its     
product candidates causes, or merely appears to have caused, an adverse         
effect or injury.  These risks will exist even for products developed that      
may be cleared for commercial sale.  If EZJR cannot successfully defend         
itself against any product liability claims, EZJR may incur substantial         
liabilities.  Regardless of merit or eventual outcome, liability claims may     
result in any one or a combination of the following:                            

o    injury to EZJR's reputation;                                     

o    withdrawal of clinical trial participants;                       

o    costs of related litigation;                                     

o    substantial monetary awards to patients or other claimants;      

o    decreased demand for EZJR's product candidates;                  

o    loss of revenues; and                                            

o    the inability to commercialize EZJR's product candidates.        

EZJR intends to secure limited product liability insurance coverage, but the    
Company may not be able to obtain such insurance on acceptable terms with       
adequate coverage, or at reasonable or affordable costs.  The amount of         
insurance coverage EZJR obtains may not be adequate to protect the Company      
from all liabilities.  EZJR may not have sufficient resources to pay for any    
liabilities resulting from a claim beyond the limit of, or excluded from, its   
insurance coverage.                                                             

  17

10-12G
18th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 18th
18. EZJR'S SOLE OFFICER/DIRECTOR AND LARGEST SHAREHOLDER OWN A CONTROLLING      
INTEREST IN EZJR'S VOTING STOCK AND SELLING SHAREHOLDERS WILL NOT HAVE ANY      
VOICE IN THE COMPANY'S MANAGEMENT, WHICH COULD RESULT IN DECISIONS ADVERSE TO   
EZJR'S GENERAL SHAREHOLDERS.                                                    

EZJR's sole officer/director and its second largest stockholder, in the         
aggregate, beneficially own approximately or have the right to vote             
approximately 68.9% of EZJR's outstanding common stock.  As a result, these     
two stockholders, acting together, will have the ability to control             
substantially all matters submitted to EZJR's stockholders for approval         
including:                                                                      

a) election of EZJR's board of directors;                                       

b) removal of any of EZJR's directors;                                          

c) amendment of EZJR's Articles of Incorporation or bylaws; and                 

d) adoption of measures that could delay or prevent a change in control or      
impede a merger, takeover or other business combination involving us.           

As a result of their ownership and positions, these two individuals have the    
ability to influence all matters requiring shareholder approval, including      
the election of directors and approval of significant corporate transactions.   
In addition, the future prospect of sales of significant amounts of shares      
held by EZJR's director and executive officer could affect the market price     
of its common stock if the marketplace does not orderly adjust to the           
increase in shares in the market and the value of shareholder investment in     
the company may decrease.  Management's stock ownership may discourage a        
potential acquirer from making a tender offer or otherwise attempting to        
obtain control of EZJR, which in turn could reduce the stock price or prevent   
the stockholders from realizing a premium over the stock price.                 

RISKS RELATING TO EZJR'S COMMON SHARES
------------------------------------- 

19.  EZJR MAY, IN THE FUTURE, ISSUE ADDITIONAL COMMON SHARES, WHICH WOULD       
REDUCE SELLING SHAREHOLDERS' PERCENT OF OWNERSHIP AND MAY DILUTE EZJR'S SHARE   
VALUE.                                                                          

The future issuance of common stock may result in substantial dilution in the   
percentage of EZJR's common stock held by EZJR's then existing shareholders.    
EZJR may value any common stock issued in the future on an arbitrary basis.     
The issuance of common stock for future services or acquisitions or other       
corporate actions may have the effect of diluting the value of the shares       
held by EZJR's selling shareholders, and might have an adverse effect on any    
trading market for EZJR's common stock.                                         

  19

10-12G
19th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 19th
20.  EZJR'S COMMON SHARES ARE SUBJECT TO THE "PENNY STOCK" RULES OF THE SEC     
AND THE TRADING MARKET IN EZJR'S SECURITIES IS LIMITED, WHICH MAKES             
TRANSACTIONS IN EZJR'S STOCK CUMBERSOME AND MAY REDUCE THE VALUE OF AN          
INVESTMENT IN EZJR'S STOCK.                                                     

The U. S. Securities and Exchange Commission has adopted Rule 15g-9 which       
establishes the definition of a "penny stock," for the purposes relevant to     
us, as any equity security that has a market price of less than $5.00 per       
share or with an exercise price of less than $5.00 per share, subject to        
certain exceptions.                                                             

For any transaction involving a penny stock, unless exempt, the rules           
require: (a) that a broker or dealer approve a person's account for             
transactions in penny stocks; and (b) the broker or dealer receive from the     
investor a written agreement to the transaction, setting forth the identity     
and quantity of the penny stock to be purchased.                                

In order to approve a person's account for transactions in penny stocks, the    
broker or dealer must: (a) obtain financial information and investment          
experience objectives of the person; and (b) make a reasonable determination    
that the transactions in penny stocks are suitable for that person and the      
person has sufficient knowledge and experience in financial matters to be       
capable of evaluating the risks of transactions in penny stocks.                

The broker or dealer must also deliver, prior to any transaction in a penny     
stock, a disclosure schedule prescribed by the Commission relating to the       
penny stock market, which, in highlight form: (a) sets forth the basis on       
which the broker or dealer made the suitability determination; and (b) that     
the broker or dealer received a signed, written agreement from the investor     
prior to the transaction. Generally, brokers may be less willing to execute     
transactions in securities subject to the "penny stock" rules.  This may make   
it more difficult for selling shareholders to dispose of EZJR's Common shares   
and cause a decline in the market value of EZJR's stock.                        

Disclosure also has to be made about the risks of investing in penny stocks     
in both public offerings and in secondary trading and about the commissions     
payable to both the broker-dealer and the registered representative, current    
quotations for the securities and the rights and remedies available to an       
investor in cases of fraud in penny stock transactions.  Finally, monthly       
statements have to be sent disclosing recent price information for the penny    
stock held in the account and information on the limited market in              
penny stocks.                                                                   

21.  ALTHOUGH OUR STOCK IS LISTED ON THE OTC-BB, A TRADING MARKET HAS NOT       
DEVELOP, PURCHASERS OF OUR SECURITIES MAY HAVE DIFFICULTY SELLING THEIR SHARES. 

There is currently no active trading market in our securities and there are no  
assurances that a market may develop or, if developed, may not be sustained.    
If no market is ever developed for our common stock, it will be difficult for   
you to sell any shares in our Company.  In such a case, you may find that you   
are unable to achieve any benefit from your investment or liquidate your shares 
without considerable delay, if at all.                                          

  20

10-12G
20th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 20th
22.  BECAUSE EZJR DOES NOT INTEND TO PAY ANY CASH DIVIDENDS ON ITS COMMON       
STOCK, THE COMPANY'S STOCKHOLDERS WILL NOT BE ABLE TO RECEIVE A RETURN ON       
THEIR SHARES UNLESS THEY SELL THEM.                                             

EZJR intends to retain any future earnings to finance the development and       
expansion of its business.  EZJR does not anticipate paying any cash            
dividends on its common stock in the foreseeable future.  Unless EZJR pays      
dividends, its stockholders will not be able to receive a return on their       
shares unless they sell them.  There is no assurance that stockholders will     
be able to sell shares when desired.                                            

23. EZJR MAY ISSUE SHARES OF PREFERRED STOCK IN THE FUTURE THAT MAY ADVERSELY   
IMPACT SHAREHOLDER RIGHTS AS HOLDERS OF THE COMPANY'S COMMON STOCK.             

EZJR's articles of incorporation authorize the Company to issue up to           
5,000,000 shares of preferred stock.  Accordingly, the board of directors       
will have the authority to fix and determine the relative rights and            
preferences of preferred shares, as well as the authority to issue such         
shares, without further stockholder approval.  As a result, the board of        
directors could authorize the issuance of a series of preferred stock that      
would grant to holders preferred rights to its assets upon liquidation, the     
right to receive dividends before dividends are declared to holders of EZJR's   
common stock, and the right to the redemption of such preferred shares,         
together with a premium, prior to the redemption of the common stock.  To the   
extent that EZJR does issue such additional shares of preferred stock, the      
shareholders rights as holders of common stock could be impaired thereby,       
including, without limitation, dilution of shareholder ownership interests in   
EZJR.  In addition, shares of preferred stock could be issued with terms        
calculated to delay or prevent a change in control or make removal of           
management more difficult, which may not be in the best interest as holders     
of common stock.                                                                

  21

10-12G
21st Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 21st
Item 2. Financial Information.                                                  

Management's Discussion and Analysis of Financial Condition and Results of      
Operations.                                                                     

Overview of Current Operations                                                  
------------------------------                                                  

EZJR, Inc., was organized by the filing of Articles of Incorporation            
with the Secretary of State of the State of Nevada on December 30, 2005.        

EZJR, Inc. is a development stage medical device company which plans to         
produce medical devices, utilizing the services contract manufacturing          
facilities.  EZJR does not have the resources to conduct any required           
clinical trials to obtain FDA approval.  Therefore, EZJR plans to outsource     
this task to third parties who have the facilities to conduct any required      
clinical trials.  EZJR also plans to subcontract the manufacturing and          
production process of any future medical device to a FDA approved contract      
manufacturing facility which can produce sterile medical devices under Good     
Manufacturing Practices.  The company plans to distribute its product(s) into   
the marketplace through medical supply wholesalers, hospitals and health        
maintenance organizations.                                                      

Results of Operations for the year ended June 30, 2009                          
------------------------------------------------------                          

We earned no revenues since our inception through June 30, 2009.  We do         
not anticipate earning any significant revenues until such time as we can       
bring to the market a medical device product.  We are presently in the          
development stage of our business and we can provide no assurance that we       
will be successful in developing any medical device products.                   

For the period inception through June 30, 2009, we generated no income.         
Since our inception on August 14, 2006 we experienced a net loss of             
$(78,381).  Our loss was attributed to organizational expenses and entering     
into a exclusive option agreement for a medical device.  We anticipate our      
operating expenses will increase as we enhance our operations.  The increase    
will be attributed to professional fees to be incurred in connection with the   
filing of a registration statement with the Securities Exchange Commission      
under the Securities Act of 1933.  We anticipate our ongoing operating          
expenses will also increase once we become a reporting company under the        
Securities Exchange Act of 1934.                                                

For the fiscal year ending June 30, 2009, we experienced a net loss of          
$(13,190) as compared to a net loss of $(28,761) for the same period last year. 
The net loss for the year ending June 30, 2009 was contributed to professional  
fees of $7,410, research and development fees of $280 and auditing fees of      
$5,500.  Our auditor issued an opinion that our financial condition raises      
substantial doubt about the Company's ability to continue as a going concern.   

  22

10-12G
22nd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 22nd
Revenues                                                                        
--------                                                                        

We generated no revenues for the period from August 14, 2006 (inception)        
through June 30, 2009.  We do not anticipate generating any revenues for at     
least 28 months.                                                                

Going Concern                                                                   
-------------                                                                   

Our independent auditors included an explanatory paragraph in their report on   
the accompanying financial statements regarding concerns about our ability to   
continue as a going concern.  Our financial statements contain additional       
note disclosures describing the circumstances that lead to this disclosure by   
our independent auditors.                                                       

Off-Balance Sheet Arrangements                                                  

We have not entered into any off-balance sheet arrangements that have or are    
reasonably likely to have a current or future effect on our financial           
condition, changes in financial condition, revenues or expenses, results of     
operations, liquidity, capital expenditures or capital resources and would be   
considered material to investors.                                               

Item 3. Properties.                                                             

Our corporate headquarters are located at 3415 Ocatillo Mesa Way, North Las     
Vegas, NV  89031.  We believe our current office space is adequate for our      
immediate needs; however, as our operations expand, we may need to locate and   
secure additional office space.                                                 

Item 4. Security Ownership of Certain Beneficial Owners and Management.         

The following table presents information, to the best of our knowledge, about   
the ownership of our common stock on October 13, 2009 relating to those         
persons known to beneficially own more than 5% of our capital stock and by      
our named executive officer and sole director. The percentage of beneficial     
ownership for the following table is based on 10,873,750 shares of common       
stock outstanding.                                                              

  23

10-12G
23rd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 23rd
Beneficial ownership is determined in accordance with the rules of the          
Securities and Exchange Commission and does not necessarily indicate            
beneficial ownership for any other purpose.  Under these rules, beneficial      
ownership includes those shares of common stock over which the stockholder      
has sole or shared voting or investment power.  It also includes shares of      
common stock that the stockholder has a right to acquire within 60 days after   
October 13, 2009 pursuant to options, warrants, conversion privileges or        
other right. The percentage ownership of the outstanding common stock,          
however, is based on the assumption, expressly required by the rules of the     
Securities and Exchange Commission, that only the person or entity whose        
ownership is being reported has converted options or warrants into shares of    
EZJR's common stock.                                                            

                                Amount
Title     Name and Address                           of shares      Percent     
of        of Beneficial                              held by          of        
Class     Owner of Shares         Position           Owner          Class(1)    
----------------------------------------------------------------------------    
Common     T J Jesky (2)          Pres./Director     4,000,000       36.7%      
Common     Mark DeStefano (3)     Shareholder        3,500,000       32.2%      
---------------------------------------------------------------------------     
All Executive Officers, Directors                                               
as a Group  (1 person)                               4,000,000       36.7%      

(1)  The percentages listed in the Percent of Class column are based upon       
10,873,750 issued and outstanding shares of Common Stock.             
(2)  T J Jesky, 2235 E. Flamingo, Suite 114, Las Vegas, NV 89119.               
(3)  Mark DeStefano, 500 N. Rainbow, Suite 300, Las Vegas, NV  89107.           

  24

10-12G
24th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 24th
Item 5. Directors and Executive Officers.                                       

(a) Identification of Directors and Executive Officers.                         

The following table sets forth certain information regarding our current        
directors and executive officers.  Our executive officers serve one-year        
terms.                                                                          

Name                         Age   Positions and Offices Held                   
---------------              ---   --------------------------                   
T J Jesky                    62    President, Secretary and Director            

The Company is managed by T J Jesky, who has 22-years experience in the         
pharmaceutical industry.  He is a former Division Manager for Procter &         
Gamble Pharmaceuticals.  He began his pharmaceutical career in 1973 with        
Norwich Pharmacal, whose headquarters were based in Norwich, New York.  This    
company subsequently changed its name to Norwich Eaton, and in 1981 it was      
purchased by Procter & Gamble.  Norwich Eaton subsequently changed its name     
to Procter & Gamble Pharmaceuticals.  Mr. Jesky held various positions in the   
company, including but not limited to:  District Manager, Key Account           
Manager, Hospital Manager, Region Manager, Division Manager for U.S., Canada    
and Puerto Rico.  He resigned from Procter & Gamble in 1995.  He became         
President, CEO and sole stockholder of Studebaker's, Inc. a                     
restaurant/nightclub and real estate holding company in Arizona.  He            
privately sold this business in 1997.  In 1997 through 1998, he owned and       
operated a restaurant consulting business, named Ionosphere, Inc.  In 1998,     
he resigned from the Company when it was acquired by Axonyx, Inc., which is     
currently trading on the NASDAQ National Market, under the name TorreyPines     
Therapeutics, Inc.  From 1996 through 1999 he was President and Chairman of     
the Board of Boppers Holdings, Inc., a Nevada Corporation real estate           
business; he resigned from the Company when it was acquired by e-Smart          
Technologies, Inc. which is currently listed on the Pink Sheets.  In August,    
1998, Mr. Jesky founded Barrington Laboratories, Inc., he resigned from the     
Company when it was acquired by ModernGroove Entertainment, in January, 2001    
and subsequently acquired by Immediatek, Inc.  Immediatek is currently traded   
on the OTC-BB.  From February, 2000 to March, 2007, he held the position as     
President/Director of Eaton Laboratories, Inc.  In March, 2007, Eaton           
Laboratories was acquired by Hydrogen Hybrid Technologies, Inc, a Canadian-     
based firm which is currently traded on OTC-BB under the stock symbol HYHY.     
From inception to present, he has held the position as President/ Director of   
IVPSA Corporation.  IVPSA Corporation was a subsidiary of Eaton Laboratories.   
IVPSA Corporation subsequently merged EZJR, Inc. EZJR, Inc.                     

(b) Family Relationships.                                                       

None.                                                                           

(c) Involvement in Certain Legal Proceedings.                                   

There have been no events under any bankruptcy act, no criminal proceedings     
and no judgments, injunctions, orders or decrees material to the evaluation     
of the ability and integrity of any director, executive officer, promoter or    
control person of the Registrant during the past five years.                    

  25

10-12G
25th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 25th
Item 6. Executive Compensation.                                                 

The Company's sole officer and sole director have not received any cash         
remuneration or compensation since inception.                                   

Summary Compensation Table                                                      
--------------------------                                                      

                                             All
              Fiscal                         Other
                Year                           Compen-
                        Ending  Salary Bonus  Awards   sation    Total
Name and Principal Position  June 30  ($)    ($)    ($)       ($)      ($)      
----------------------------------------------------------------------------    
T J Jesky          CEO/Dir.  2009    -0-    -0-      -0-     -0-        -0-     
                        2008    -0-    -0-      -0-     -0-        -0-
                        2007    -0-    -0-      -0-     -0-        -0-

No retirement, pension, profit sharing, stock option or insurance programs      
or other similar programs have been adopted by the Company for the benefit      
of its employees.                                                               

We do not have any employment agreements with our officers/directors.  We do    
not maintain key-man life insurance for any our executive officers/directors.   
We do not have any long-term compensation plans or stock option plans.          

Stock Option Grants                                                             
-------------------                                                             

We did not grant any stock options to the executive officers or directors       
from inception through fiscal year end June 30, 2009.                           

Outstanding Equity Awards at Fiscal Year-Ending June 30, 2009                   
-------------------------------------------------------------                   

We did not have any outstanding equity awards as of June 30, 2009.              

Option Exercises for Fiscal Year-Ending June 30, 2009                           
-----------------------------------------------------                           

There were no options exercised by our named executive officer in               
fiscal year ending June 30, 2009.                                               

  26

10-12G
26th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 26th
Potential Payments upon Termination or Change in Control                        
--------------------------------------------------------                        

We have not entered into any compensatory plans or arrangements with respect    
to our named executive officer, which would in any way result in payments to    
such officer because of his resignation, retirement, or other termination of    
employment with us or our subsidiaries, or any change in control of, or a       
change in his responsibilities following a change in control.                   

Director Compensation                                                           
---------------------                                                           

We did not pay our directors any compensation during fiscal years ending        
June 30, 2009 or June 30, 2008.                                                 

Item 7. Certain Relationships and Related Transactions, and Director            
Independence.                                                                   

Through a Board Resolution and the approval of the majority of shareholders     
at the Company's annual shareholder meeting, the Company hired the              
professional services of Seale and Beers, CPAs, Certified Public Accountants,   
to perform an audit of the financial statements of the Company.  Seale and      
Beers, CPAs own no stock in the Company.  The company has no formal contracts   
with its accountants and they are paid on a fee for service basis.              

Except as otherwise indicated herein, there have been no related party          
transactions, or any other transactions or relationships required to be         
disclosed pursuant to Item 404 and Item 407(a) of Regulation S-K.               

Item 8. Legal Proceedings.                                                      

There are presently no material pending legal proceedings to which the          
Registrant is a party or as to which any of its property is subject, and no     
such proceedings are known to the Registrant to be threatened or                
contemplated against it.                                                        

  27

10-12G
27th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 27th
Item 9. Market Price of and Dividends on the Registrant's Common Equity and     
Related Stockholder Matters.                                                    

(a) Market Information                                                          

Your Event, Inc. Common Stock, $0.001 par value, is traded on the OTC-Bulletin  
Board under the symbol:  EZJR.  The stock was cleared for trading on the OTC-   
Bulletin Board on June 22, 2009.                                                

Since the Company has been cleared for trading, through October 6, 2009,        
there have been no trades of the Company's stock.  There are no assurances that 
a market will ever develop for the Company's stock.                             

(b) Holders of Common Stock                                                     

As of September 23, 2008, there were approximately 100 holders of record of     
our Common Stock and 10,873,750 shares outstanding.                             

(c) Dividends                                                                   

In the future we intend to follow a policy of retaining earnings, if any, to    
finance the growth of the business and do not anticipate paying any cash        
dividends in the foreseeable future.  The declaration and payment of future     
dividends on the Common Stock will be the sole discretion of board of           
directors and will depend on our profitability and financial condition,         
capital requirements, statutory and contractual restrictions, future            
prospects and other factors deemed relevant.                                    

(d) Securities Authorized for Issuance under Equity Compensation Plans          

There are no outstanding grants or rights or any equity compensation plan in    
place.                                                                          

(e)  Recent Sales of Unregistered Securities                                    

The Company did not issue any shares during the fiscal years ended              
June 30, 2009 or June 30, 2008.                                                 

(f)  Issuer Purchases of Equity Securities                                      

We did not repurchase any of our equity securities during the years ended       
June 30, 2009 or June 30, 2008.                                                 

  28

10-12G
28th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 28th
Item 10. Recent Sales of Unregistered Securities.                               

EZJR, Inc. was a wholly-owned subsidiary of Eaton Laboratories.  The shares     
of EZJR were issued to each of Eaton's shareholders as a spin-off dividend of   
Eaton Laboratories, Inc. in October, 2006.  There have been no other            
issuances of stock.                                                             

The Company did not issue any shares during the fiscal years ended June 30,     
2009, June 30, 2008 or June 30, 2007.  No securities have been issued for       
services.  Neither the Registrant nor any person acting on its behalf           
offered or sold the securities by means of any form of general solicitation     
or general advertising. No services were performed by any purchaser as          
consideration for the shares issued.                                            

Item 11. Description of Registrant's Securities to be Registered.               

(a) Capital Stock.                                                              

The Company is authorized by its Certificate of Incorporation to issue an       
aggregate of 75,000,000 shares of capital stock, of which 70,000,000 are        
shares of Common Stock and 5,000,000 are shares of Preferred Stock.  As of      
October 13, 2009, 10,873,750 shares of Common Stock and zero shares of          
Preferred Stock were issued and outstanding.                                    

Common Stock                                                                    

All outstanding shares of Common Stock are of the same class and have equal     
rights and attributes.  The holders of Common Stock are entitled to one vote    
per share on all matters submitted to a vote of stockholders of the Company.    
All stockholders are entitled to share equally in dividends, if any, as may be  
declared from time to time by the Board of Directors out of funds legally       
available.  In the event of liquidation, the holders of Common Stock are        
entitled to share ratably in all assets remaining after payment of all          
liabilities. The stockholders do not have cumulative or preemptive rights.      

Preferred Stock                                                                 

Our Certificate of Incorporation authorizes the issuance of up to 5,000,000     
shares of Preferred Stock with designations, rights and preferences             
determined from time to time by its Board of Directors.  Accordingly, our       
Board of Directors is empowered, without stockholder approval, to issue         
Preferred Stock with dividend, liquidation, conversion, voting, or other        
rights which could adversely affect the voting power or other rights of the     
holders of the Common Stock. In the event of issuance, the Preferred Stock      
could be utilized, under certain circumstances, as a method of discouraging,    
delaying or preventing a change in control of the Company. Although we have     
no present intention to issue any shares of our authorized Preferred Stock,     
there can be no assurance that the Company will not do so in the future.        

  29

10-12G
29th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 29th
The description of certain matters relating to the securities of the Company    
is a summary and is qualified in its entirety by the provisions of the          
Company's Certificate of Incorporation and By-Laws, copies of which have been   
filed as exhibits to this Form 10.                                              

(b) Debt Securities.                                                            

None.                                                                           

(c) Warrants and Rights.                                                        

None.                                                                           

(d) Other Securities to Be Registered.                                          

None.                                                                           

Item 12. Indemnification of Directors and Officers.                             

Our Articles and By-laws provide to the fullest extent permitted by law, our    
directors or officers, former directors and officers, and persons who act at    
our request as a director or officer of a body corporate of which we are a      
shareholder or creditor shall be indemnified by us.  We believe that the        
indemnification provisions in our By-laws are necessary to attract and retain   
qualified persons as directors and officers.  Insofar as indemnification for    
liabilities arising under the Securities Act of 1933 (the "Act" or "Securities  
Act") may be permitted to directors, officers or persons controlling us         
pursuant to the foregoing provisions, or otherwise, we have been advised that   
in the opinion of the Securities and Exchange Commission, such                  
indemnification is against public policy as expressed in the Act and is,        
therefore, unenforceable.                                                       

Item 13. Financial Statements and Supplementary Data.                           

We set forth below a list of our audited financial statements included in       
this Registration Statement on Form 10.                                         

                                                          PAGE
                                                          ----
Independent Auditors' Report                                       F-1          
Balance Sheet                                                      F-2          
Statements of Operations                                           F-3          
Statements of Changes in Stockholders' Equity                      F-4-5        
Statements of Cash Flows                                           F-6          
Notes to Financials                                                F-7          
------------                                                                    
*Page F-1 follows page 32 to this Registration Statement on Form 10.            

  30

10-12G
30th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 30th
Item 14. Changes in and Disagreements with Accountants on Accounting and        
Financial Disclosure.                                                           

There are not and have not been any disagreements between the Registrant        
and its accountants on any matter of accounting principles, practices or        
financial statement disclosure.                                                 

Item 15. Financial Statements and Exhibits.                                     

(a) Financial Statements.                                                       

The financial statements included in this Registration Statement on Form 10     
are listed in Item 13 and commence following page 20.                           

(b) Financial Statement Schedules                                               

None.                                                                           

(c) Exhibit Index                                                               
                                           Incorporated by reference
                                           -------------------------
                                      Filed          Period           Filing
Exhibit       Exhibit Description     herewith  Form   ending  Exhibit   date   
------------------------------------------------------------------------------  
2.1        Acquisition and Plan of              8-K              2.1   7/28/08  
Merger between EZJR, Inc.                                 
and IVPSA Corporation                                     
dated July 25, 2008.                                      
------------------------------------------------------------------------------  
3.1        Articles of Incorporation,           10-K   6/30/08   3.1   9/25/08  
as currently in effect                                    
------------------------------------------------------------------------------  
3.2        Bylaws                               10-K   6/30/08   3.3   9/25/08  
as currently in effect                                    
------------------------------------------------------------------------------  
3.3        Articles of Merger                   10-K   6/30/08   3.3   9/25/08  
between EZJR, Inc. and                                    
IVPSA Corporation                                         
------------------------------------------------------------------------------  
10.1       Exclusive Option Agreement           8-K             10.1   7/28/08  
between IVPSA Corporation                                 
and the Cleveland Clinic,                                 
dated March 15, 2007                                      
------------------------------------------------------------------------------  
10.2       Extension of Exclusive               8-K             10.2   7/28/08  
Option Agreement between                                  
IVPSA Corporation and                                     
the Cleveland Clinic,                                     
dated April 14, 2008.                                     
------------------------------------------------------------------------------  
23.1       Consent Letter from Seale     X                                      
and Beers, CPAs                                           
------------------------------------------------------------------------------  

  31

10-12G
31st Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 31st
SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act       
of 1934, the registrant has duly caused this registration statement to be       
signed on its behalf by the undersigned, thereunto duly authorized.             

Date:  October 13, 2009                EZJR, Inc.                               

                 By:  /s/  T J Jesky
                   ---------------------
                           T J Jesky
                                      President, Secretary
                          Director
                                             Principal Executive Officer

  32

10-12G
32nd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 32nd
SEALE AND BEERS, CPAs                                                           
PCAOB & CPAB REGISTERED AUDITORS                                                
--------------------------------                                                
www.sealebeers.com                                                              

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   
-------------------------------------------------------   

To the Board of Directors                                                       
EZJR, Inc.                                                                      
(A Development Stage Company)                                                   

We have audited the accompanying balance sheet of EZJR, Inc. (A Development     
Stage Company) as of June 30, 2009 and 2008, and the related statements of      
operations, stockholders' equity (deficit) and cash flows for the years then    
ended, and for the period from inception on August 14, 2006 through June 30,    
2009. These financial statements are the responsibility of the Company's        
management.  Our responsibility is to express an opinion on these financial     
statements based on our audits.                                                 

We conduct our audits in accordance with standards of the Public Company        
Accounting Oversight Board (United States).  Those standards require that we    
plan and perform the audits to obtain reasonable assurance about whether the    
financial statements are free of material misstatement.  An audit includes      
examining, on a test basis, evidence supporting the amounts and disclosures     
in the financial statements.  An audit also includes assessing the accounting   
principles used and significant estimates made by management, as well as        
evaluating the overall financial statement presentation.  We believe that our   
audits provide a reasonable basis for our opinion.                              

In our opinion, the financial statements referred to above present fairly, in   
all material respects, the financial position of EZJR, Inc. (A Development      
Stage Company) as of June 30, 2009 and 2008, and the related statements of      
operations, stockholders' equity (deficit) and cash flows for the years then    
ended, and for the period from inception on August 14, 2006 through June 30,    
2009, in conformity with accounting principles generally accepted in the        
United States of America.                                                       

The accompanying financial statements have been prepared assuming that the      
Company will continue as a going concern.  As discussed in Note 3 to the        
financial statements, the Company has an accumulated deficit of $78,381,        
which raises substantial doubt about its ability to continue as a going         
concern.  Management's plans concerning these matters are also described in     
Note 3.  The financial statements do not include any adjustments that might     
result from the outcome of this uncertainty.                                    

/s/ Seale and Beers, CPAs                                                       
-------------------------                                                       
Seale and Beers, CPAs                                                   
Las Vegas, Nevada                                                       
October 10, 2009                                                        

6490 West Desert Inn Rd, Las Vegas, NV 89146 (702) 253-7492 Fax (702) 253-7501  

F-1 

10-12G
33rd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 33rd
EZJR, Inc.  
(A Development Stage Company)   
Balance Sheets  

                                                                [Download Table]


                                               June 30,       June 30,   
                                                 2009           2008     
                                              -----------   -------------
                                                                         
ASSETS                                                                   

Current assets:                                                          
   Funds in escrow                            $         -   $      7,500 
   Prepaid expenses                           $     3,500   $          - 
                                              -----------   -------------
     Total current assets                           3,500          7,500 
                                              ------------  -------------
TOTAL ASSETS                                  $     3,500   $      7,500 
                                              ===========   =============

LIABILITIES AND STOCKHOLDERS' EQUITY                                     

Current Liabilities:                                                     
   Accounts payable                           $     1,480   $     15,757 
   Accrued expense                                  2,500              - 
                                              ------------  -------------
     Total liabilities                              3,980         15,757 
                                              ------------  -------------

Stockholders' equity:                                                    
   Preferred stock, $0.001 par value,                                    
     5,000,000 shares authorized,                                        
     none issued                                        -              - 
   Common stock, $0.001 par value, 70,000,000                            
    shares authorized, 10,873,750 shares and                             
     and 10,873,750 issued and outstanding                               
     as of 6/30/09 and 6/30/08 respectively        10,873         10,873 
   Additional paid-in capital                      67,028         46,061 
   (Deficit) accumulated during development                              
    stage                                         (78,381)       (65,191)
                                              ------------  -------------
     Total stockholders' equity                      (480)        (8,257)
                                              ------------  -------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY    $     3,500   $      7,500 
                                              ============  =============

The accompanying notes are an integral part of these financial statements.

F-2 

10-12G
34th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 34th
EZJR, Inc.  
(A Development Stage Company)   
Statements of Operations    

                                                                [Download Table]


                                                        August 14,   
                                  For the years            2006      
                                 ended June 30,       (inception) to 
                            ------------------------      June 30,   
                                2009         2008           2009     
                            -----------  -----------   --------------
                                                                     
REVENUE                     $         -  $        -    $           - 
                            -----------  -----------   --------------

EXPENSES:                                                            
  Audit fees                     5,500        1,500            7,000 
  Incorporating fees                 -            -              430 
  Option contract                    -       10,000           46,000 
  Professional fees              7,410          504            7,914 
  Research & Development           280       16,757           17,037 
                            -----------  -----------   --------------
   Total expenses               13,190       28,761           78,381 
                            -----------  -----------   --------------

Net (loss) before income                                             
 taxes                         (13,190)     (28,761)         (78,381)

Income tax expense                   -             -               - 
                            -----------  -----------   --------------

NET (LOSS)                  $  (13,190)  $  (28,761)   $     (78,381)
                            ===========  ===========   ==============

NET (LOSS) PER COMMON                                                
 SHARE                      $    (0.00)  $    (0.00)                 
                            ===========  ===========                 

WEIGHTED AVERAGE NUMBER OF                                           
 COMMON SHARES OUTSTANDING  10,873,750   10,873,750                  
                            ===========  ===========                 

The accompanying notes are an integral part of these financial statements.  

F-3 

10-12G
35th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 35th
EZJR, Inc.    
(A Development Stage Company)     
Statements of Stockholders' Deficit     

                                                                [Download Table]


                                                    (Deficit)                
           Preferred                                Accumulated              
             Stock        Common Stock   Additional  During                  
         ------------- ------------------ Paid-in   Development              
         Shares Amount   Shares   Amount  Capital    Stage         Total     
         ------ ------ ---------- ------- -------- ---------- -------------- 
                                                                             
August 14,                                                                   
2006                                                                         
Contributed                                                                  
capital                                    36,430                    36,430  

August 14,                                                                   
2006                                                                         
stock issued                                                                 
as a dividend                                                                
from Eaton                                                                   
Laboratories                                                                 
at $0.001                                                                    
per share              10,873,750  10,873 (10,873)                        -  

Net (loss)                                                                   
for the                                                                      
year ended                                                                   
June 30,                                                                     
2007                                                 (36,430)       (36,430) 
         ------ ------ ---------- ------- -------- ---------- -------------- 

Balance,                                                                     
June 30,                                                                     
2007          -      - 10,873,750  10,873   25,557   (36,430)             -  

February 2008                                                                
Contributed                                                                  
capital                                      2,500                    2,500  

April 2008                                                                   
Contributed                                                                  
capital                                     10,000                   10,000  

June 2008                                                                    
Contributed                                                                  
capital                                      8,004                    8,004  

                                      F-4                                    

10-12G
36th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 36th
                                 EZJR, Inc.                                  
                       (A Development Stage Company)                         
               Statements of Stockholders' Deficit (Continued)               

                                                    (Deficit)                
           Preferred                                Accumulated              
             Stock        Common Stock   Additional  During                  
         ------------- ------------------ Paid-in   Development              
         Shares Amount   Shares   Amount  Capital    Stage         Total     
         ------ ------ ---------- ------- -------- ---------- -------------- 
Net (loss)                                                                   
for the                                                                      
year ended                                                                   
June 30,                                                                     
2008                                                 (28,761)       (28,761) 
         ------ ------ ---------- ------- -------- ---------- -------------- 

Balance,                                                                     
June 30,                                                                     
2008          -     -  10,873,750  10,873  46,061    (65,191)        (8,257) 

September                                                                    
2008                                                                         
Contributed                                                                  
capital                                      1,500                     1,500 

December                                                                     
2008                                                                         
Contributed                                                                  
capital                                     19,467                    19,467 

Net (loss)                                                                   
for the                                                                      
year ended                                                                   
June 30,                                                                     
2009                                                  (13,190)       (13,190)
         ------ ------ ---------- ------- -------- ----------- --------------

Balance,                                                                     
June 30,                                                                     
2009          - $    - 10,873,750 $10,873 $67,028  $  (78,381) $        (480)
         ====== ====== ========== ======= ======== =========== ==============

The accompanying notes are an integral part of these financial statements.  

F-5 

10-12G
37th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 37th
EZJR, Inc.      
(A Development Stage Company)     
Statements of Cash Flows    

                                                                [Download Table]


                                                                 August 14,  
                                         For the years              2006     
                                         ended June 30,        (inception) to
                                     ------------------------     June 30,   
                                          2009       2008           2009     
                                     -----------  -----------  --------------
                                                                             
OPERATING ACTIVITIES:                                                        
Net (loss)                           $  (13,190)  $  (28,761)  $     (78,381)
Adjustments to reconcile net loss                                            
 to net cash provided (used) by                                              
 operating activities:                                                       
   (Increase) in prepaid expense         (3,500)           -          (3,500)
   (Decrease) increase in accounts                                           
      payable                           (14,277)      15,757           1,480 
   Increase in accrued expense            2,500            -           2,500 
                                     -----------  -----------  --------------
Net cash (used) by operating                                                 
  activities                            (28,467)     (13,004)        (77,901)
                                     -----------  -----------  --------------

FINANCING ACTIVITIES:                                                        
Contributed capital                      20,967       20,504          77,901 
                                     -----------  -----------  --------------
Net cash provided by financing                                               
  activities                             20,967       20,504          77,901 
                                     -----------  -----------  --------------

NET INCREASE (DECREASE) IN CASH          (7,500)       7,500               - 
CASH AND EQUIVALENTS - BEGINNING          7,500            -               - 
                                     -----------  -----------  --------------
CASH AND EQUIVALENTS - ENDING        $        -   $    7,500   $           - 
                                     ===========  ===========  ==============

SUPPLEMENTAL DISCLOSURES:                                                    
   Interest paid                     $        -   $        -   $           - 
                                     ===========  ===========  ==============
   Income taxes paid                 $        -   $        -   $           - 
                                     ===========  ===========  ==============
   Non-cash transactions             $        -   $        -   $           - 
                                     ===========  ===========  ==============

The accompanying notes are an integral part of these financial statements.  

F-6 

10-12G
38th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 38th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 1.   General Organization and Business                                     

The Company was organized August 14, 2006 (Date of Inception) under the laws    
of the State of Nevada, as IVPSA Corporation.  The Company was incorporated     
as a wholly owned subsidiary of Eaton Laboratories, Inc., a Nevada              
corporation. Eaton Laboratories was incorporated February 2, 2002, and, at      
the time of spin off was listed on the Over the Counter Bulletin Board.         

The directors of Eaton Laboratories approved a spin off of its IVPSA subsidiary 
in the form of a stock dividend as of November 1, 2006 (the "Record Date").     
The record shareholders of Eaton received one (1) unregistered common share,    
par value $0.001, of IVPSA Corporation common stock for every share of Eaton    
Laboratories common stock owned.  The IVPSA Corporation stock dividend was      
based on 10,873,750 shares of Eaton common stock that were issued and           
outstanding as of the record date.  Since IVPSA's business was related to       
developing medical devices and Eaton's business was related to developing       
generic pharmaceutical products, the Eaton directors decided it was in the      
best interest of Eaton and IVPSA's shareholders to spin off IVPSA to minimize   
any potential of conflict of interest, in accessing funding.                    

The spin-off transaction was accomplished by the distribution of certain        
intellectual property, representing industry contacts, third party              
relationships and trade secrets.  It did not include the transfer of any hard   
assets or liabilities.  This spin off was valued at par value since the         
company held no assets, was uncertain as to future benefit, the stock was not   
trading, and the company did not yet receive a stock symbol.                    

Eaton retained no ownership in IVPSA Corporation following the spin off.        
IVPSA Corporation is no longer a subsidiary of Eaton Laboratories.              

The Company is a development stage enterprise in accordance with Statement of   
Financial Accounting Standards ("SFAS") No. 7, "Accounting and Reporting by     
Development Stage Enterprises".  The Company plans to develop and market        
medical devices.                                                                

NOTE 2.    Summary of Significant Accounting Practices                          

The Company has assets of $3,500 in prepaid expenses and liabilities of         
$3,980 as of June 30, 2009. The relevant accounting policies are listed         
below.                                                                          

Basis of Accounting                                                             
-------------------                                                             
The basis is United States generally accepted accounting principles.            

F-7 

10-12G
39th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 39th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 2.    Summary of Significant Accounting Practices (Continued)              

Earnings per Share                                                              
------------------                                                              
The basic earnings (loss) per share is calculated by dividing the Company's     
net income (loss) available to common shareholders by the weighted average      
number of common shares during the year.  The diluted earnings (loss) per       
share is calculated by dividing the Company's net income (loss) available to    
common shareholders by the diluted weighted  average number of shares           
outstanding during the year.  The diluted weighted average number of shares     
outstanding is the basic weighted number of shares adjusted as of the first     
of the year for any potentially dilutive debt or equity.                        

The Company has not issued any options or warrants or similar securities        
since inception.                                                                

Revenue recognition                                                             
-------------------                                                             
The Company recognizes revenue on an accrual basis as it invoices for           
services.                                                                       

Dividends                                                                       
---------                                                                       
The Company has not yet adopted any policy regarding payment of dividends.      
No Dividends have been paid during the period shown.                            

Income Taxes                                                                    
------------                                                                    
The provision for income taxes is the total of the current taxes payable and    
the net of the change in the deferred income taxes.  Provision is made for      
the deferred income taxes where differences exist between the period in which   
transactions affect current taxable income and the period in which they enter   
into the determination of net income in the financial statements.               

Year-end                                                                        
--------                                                                        
The Company originally selected December 31 as its year-end.  On March 31,      
2008 the board of directors and majority of shareholders accepted a             
change of the year-end to June 30.                                              

Advertising                                                                     
-----------                                                                     
Advertising is expensed when incurred.  There has been no advertising           
during the period.                                                              

F-8 

10-12G
40th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 40th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 2.    Summary of Significant Accounting Practices (Continued)              

Use of Estimates                                                                
----------------                                                                
The preparation of financial statements in conformity with accounting           
principles generally accepted in the United States of America requires          
management to make estimates and assumptions that affect the reported           
amounts of assets and liabilities and disclosure of contingent assets and       
liabilities at the date of the financial statements and the reported amounts    
of revenue and expenses during the reporting period.  Actual results could      
differ from those estimates.                                                    

NOTE 3 - Going concern                                                          

The accompanying financial statements have been prepared in conformity          
with accounting principles generally accepted in the United States of           
America, which contemplates continuation of the Company as a going concern.     
As shown in the accompanying financial statements, the Company is a             
development stage company with no history of operations, limited assets, and    
has incurred operating losses since inception. These factors, among others,     
raise substantial doubt about its ability to continue as a going concern.       

The financial statements do not include any adjustments relating to the         
recoverability of assets and classification of liabilities that might be        
necessary should the Company be unable to continue as a going concern. The      
Company's continuation as a going concern is dependent upon its ability to      
obtain additional operating capital, commence operations, provide competitive   
services, and ultimately to attain profitability. The Company intends to        
acquire additional operating capital through equity offerings. There is no      
assurance that the Company will be successful in raising additional funds.      

NOTE 4 - Stockholders' equity                                                   

The Company is authorized to issue 70,000,000 shares of its $0.001 par value    
common stock and 5,000,000 shares of its $0.001 par value preferred stock.      

The Company was a subsidiary of Eaton Laboratories, Inc.  On November 1,        
2006, the record shareholders of Eaton received a spin off dividend of one      
(1) common share, par value $0.001, of IVPSA Corporation common stock for       
every share of Eaton Laboratories common stock owned.                           

As of June 30, 2009, EZJR, Inc. has 10,873,750 of its common                    
stock issued and outstanding and none of its preferred stock issued nor         
outstanding.                                                                    

There have been no other issuances of common stock.                             

F-9 

10-12G
41st Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 41st
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 5.   Related Party Transactions                                            

The Company does not lease or rent any property.  Office space is being         
provided by the Company's director on a rent free basis.  The amount is not     
considered material to the financial statements.  The Company believes that     
its current facilities are adequate for its needs through the next twelve       
months, and that, should it be needed, suitable additional space will be        
available to accommodate expansion of the Company's operations on               
commercially reasonable terms, although there can be no assurance in this       
regard                                                                          

The sole officer and director of the Company is involved in other business      
activities and may, in the future, become involved in other business            
opportunities.  If a specific business opportunity becomes available, such      
persons may face a conflict in selecting between the Company and their other    
business interests.  The Company has not formulated a policy for the            
resolution of such conflicts.                                                   

The sole officer and director of the Company is not compensated for his         
services.  The Company does not anticipate paying compensation to any           
officer/director until the Company can generate a profit on a regular basis.    
Further, the executive officer/director of the Company has no plans to take     
any salary until the Company can generate a profit on a regular basis.          
There are no Employment Agreements in place, and the sole officer/director      
will not be compensated for services previously provided.  He will receive no   
accrued remuneration.                                                           

The sole officer/director has contributed funds to the operations of the        
Company, in order to keep it fully reporting and operational for the next       
twelve (12) months, without seeking reimbursement for funds contributed.        

NOTE 6.    Provision for Income Taxes                                           

The Company accounts for income taxes under Statement of Financial Accounting   
Standards No. 109, "Accounting for Income Taxes" ("SFAS No. 109"), which        
requires use of the liability method.  SFAS No. 109 provides that deferred      
tax assets and liabilities are recorded based on the differences between the    
tax bases of assets and liabilities and their carrying amounts for financial    
reporting purposes, referred to as temporary differences.  Deferred tax         
assets and liabilities at the end of each period are determined using the       
currently enacted tax rates applied to taxable income in the periods in which   
the deferred tax assets and liabilities are expected to be settled or           
realized.                                                                       

F-10  

10-12G
42nd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 42nd
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 6.    Provision for Income Taxes  (Continued)                              

The provision for income taxes differs from the amount computed by applying     
the statutory federal income tax rate to income before provision for income     
taxes.  The sources and tax effects of the differences are as follows:          

U.S federal statutory rate      (34.0%)   
Valuation reserve                34.0%    
                            ------
Total                               -%    

NOTE 7.   Operating Leases and Other Commitments                                

The Company has no lease or other obligations.                                  

NOTE 8.   Recent Pronouncements                                                 

June 2009, the FASB issued SFAS No. 166, "Accounting for Transfers of           
Financial Assets - an amendment of FASB Statement No. 140" ("SFAS               
166"). The provisions of SFAS 166, in part, amend the derecognition             
guidance in FASB Statement No. 140, eliminate the exemption from                
consolidation for qualifying special-purpose entities and require               
additional disclosures. SFAS 166 is effective for financial asset               
transfers occurring after the beginning of an entity's first fiscal             
year that begins after November 15, 2009. The Company does not expect           
the provisions of SFAS 166 to have a material effect on the financial           
position, results of operations or cash flows of the Company.                   

In June 2009, the FASB issued SFAS No. 167, "Amendments to FASB                 
Interpretation No. 46(R) ("SFAS 167"). SFAS 167 amends the                      
consolidation guidance applicable to variable interest entities. The            
provisions of SFAS 167 significantly affect the overall consolidation           
analysis under FASB Interpretation No. 46(R). SFAS 167 is effective as          
of the beginning of the first fiscal year that begins after November            
15, 2009. SFAS 167 will be effective for the Company beginning in 2010.         
The Company does not expect the provisions of SFAS 167 to have a                
material effect on the financial position, results of operations or             
cash flows of the Company.                                                      

F-11  

10-12G
43rd Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 43rd
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 8.   Recent Pronouncements (Continued)                                     

In June 2009, the FASB issued SFAS No. 168, "The FASB Accounting                
Standards Codification and the Hierarchy of Generally Accepted                  
Accounting Principles - a replacement of FASB Statement No. 162" ("SFAS         
No. 168"). Under SFAS No. 168 the "FASB Accounting Standards                    
Codification" ("Codification") will become the source of authoritative          
U. S. GAAP to be applied by nongovernmental entities.  Rules and                
interpretive releases of the Securities and Exchange Commission ("SEC")         
under authority of federal securities laws are also sources of                  
authoritative GAAP for SEC registrants. SFAS No. 168 is effective for           
financial statements issued for interim and annual periods ending after         
September 15, 2009.  On the effective date, the Codification will               
supersede all then-existing non-SEC accounting and reporting standards.         
All other non-grandfathered non-SEC accounting literature not included          
in the Codification will become non-authoritative. SFAS No. 168 is              
effective for the Company's interim quarterly period beginning July 1,          
2009. The Company does not expect the adoption of SFAS No. 168 to have          
an impact on the financial statements.                                          

In June 2009, the Securities and Exchange Commission's Office of the            
Chief Accountant and Division of Corporation Finance announced the              
release of Staff Accounting Bulletin (SAB) No. 112. This staff                  
accounting bulletin amends or rescinds portions of the interpretive             
guidance included in the Staff Accounting Bulletin Series in order to           
make the relevant interpretive guidance consistent with current                 
authoritative accounting and auditing guidance and Securities and               
Exchange Commission rules and regulations. Specifically, the staff is           
updating the Series in order to bring existing guidance into conformity         
with recent pronouncements by the Financial Accounting Standards Board,         
namely, Statement of Financial Accounting Standards No. 141 (revised            
2007), Business Combinations, and Statement of Financial Accounting             
Standards No. 160, Non-controlling Interests in Consolidated Financial          
Statements. The statements in staff accounting bulletins are not rules          
or interpretations of the Commission, nor are they published as bearing         
the Commission's official approval. They represent interpretations and          
practices followed by the Division of Corporation Finance and the               
Office of the Chief Accountant in administering the disclosure                  
requirements of the Federal securities laws.                                    

F-12

10-12G
44th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 44th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 8.   Recent Pronouncements (Continued)                                     

In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, Interim          
Disclosures about Fair Value of Financial Instruments. This FSP amends          
FASB Statement No. 107, Disclosures about Fair Value of Financial               
Instruments, to require disclosures about fair value of financial               
instruments for interim reporting periods of publicly traded companies          
as well as in annual financial statements. This FSP also amends APB             
Opinion No. 28, Interim Financial Reporting, to require those                   
disclosures in summarized financial information at interim reporting            
periods. This FSP shall be effective for interim reporting periods              
ending after June 15, 2009. The Company does not have any fair value of         
financial instruments to disclose.                                              

In April 2009, the FASB issued FSP No. FAS 115-2 and FAS 124-2,                 
Recognition and Presentation of Other-Than-Temporary Impairments. This          
FSP amends the other-than-temporary impairment guidance in U.S. GAAP            
for debt securities to make the guidance more operational and to                
improve the presentation and disclosure of other-than-temporary                 
impairments on debt and equity securities in the financial statements.          
The FSP does not amend existing recognition and measurement guidance            
related to other-than-temporary impairments of equity securities. The           
FSP shall be effective for interim and annual reporting periods ending          
after June 15, 2009. The Company currently does not have any financial          
assets that are other-than-temporarily impaired.                                

In April 2009, the FASB issued FSP No. FAS 141(R)-1, Accounting for             
Assets Acquired and Liabilities Assumed in a Business Combination That          
Arise from Contingencies, to address some of the application issues             
under SFAS 141(R). The FSP deals with the initial recognition and               
measurement of an asset acquired or a liability assumed in a business           
combination that arises from a contingency provided the asset or                
liability's fair value on the date of acquisition can be determined.            
When the fair value can-not be determined, the FSP requires using the           
guidance under SFAS No. 5, Accounting for Contingencies, and FASB               
Interpretation (FIN) No. 14, Reasonable Estimation of the Amount of a           
Loss. This FSP was effective for assets or liabilities arising from             
contingencies in business combinations for which the acquisition date           
is on or after January 1, 2009. The adoption of this FSP has not had a          
material impact on our financial position, results of operations, or            
cash flows during the six months ended June 30, 2009.                           

F-13  

10-12G
45th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 45th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 8.   Recent Pronouncements (Continued)                                     

In April 2009, the FASB issued FSP No. FAS 157-4, "Determining Fair             
Value When the Volume and Level of Activity for the Asset or Liability          
Have Significantly Decreased and Identifying Transactions That Are Not          
Orderly" ("FSP FAS 157-4"). FSP FAS 157-4 provides guidance on                  
estimating fair value when market activity has decreased and on                 
identifying transactions that are not orderly. Additionally, entities           
are required to disclose in interim and annual periods the inputs and           
valuation techniques used to measure fair value. This FSP is effective          
for interim and annual periods ending after June 15, 2009. The Company          
does not expect the adoption of FSP FAS 157-4 will have a material              
impact on its financial condition or results of operation.                      

In December 2008, the FASB issued FSP No. FAS 140-4 and FIN 46(R)-8,            
"Disclosures by Public Entities (Enterprises) about Transfers of                
Financial Assets and Interests in Variable Interest Entities." This             
disclosure-only FSP improves the transparency of transfers of financial         
assets and an enterprise's involvement with variable interest entities,         
including qualifying special-purpose entities. This FSP is effective            
for the first reporting period (interim or annual) ending after                 
December 15, 2008, with earlier application encouraged. The Company             
adopted this FSP effective January 1, 2009. The adoption of the FSP had         
no impact on the Company's results of operations, financial condition           
or cash flows.                                                                  

In December 2008, the FASB issued FSP No. FAS 132(R)-1, "Employers'             
Disclosures about Postretirement Benefit Plan Assets" ("FSP FAS 132(R)-         
1"). FSP FAS 132(R)-1 requires additional fair value disclosures about          
employers' pension and postretirement benefit plan assets consistent            
with guidance contained in SFAS 157.  Specifically, employers will be           
required to disclose information about how investment allocation                
decisions are made, the fair value of each major category of plan               
assets and information about the inputs and valuation techniques used           
to develop the fair value measurements of plan assets. This FSP is              
effective for fiscal years ending after December 15, 2009. The Company          
does not expect the adoption of FSP FAS 132(R)-1 will have a material           
impact on its financial condition or results of operation.                      

In October 2008, the FASB issued FSP No. FAS 157-3, "Determining the            
Fair Value of a Financial Asset When the Market for That Asset is Not           
Active," ("FSP FAS 157-3"), which clarifies application of SFAS 157 in          
a market that is not active.  FSP FAS 157-3 was effective upon                  
issuance, including prior periods for which financial statements have           
not been issued. The adoption of FSP FAS 157-3 had no impact on the             
Company's results of operations, financial condition or cash flows.             

F-14  

10-12G
46th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 46th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 8.   Recent Pronouncements (Continued)                                     

In September 2008, the FASB issued exposure drafts that eliminate               
qualifying special purpose entities from the guidance of SFAS No. 140,          
"Accounting for Transfers and Servicing of Financial  Assets and                
Extinguishments of Liabilities," and FASB Interpretation 46 (revised            
December 2003), "Consolidation of Variable Interest Entities - an               
interpretation of ARB  No. 51," as well as other modifications.  While          
the proposed revised pronouncements have not been finalized and the             
proposals are subject to further public comment, the Company                    
anticipates the changes will not have a significant impact on the               
Company's financial statements.  The changes would be effective March           
1, 2010, on a prospective basis.                                                

In June 2008, the FASB issued FASB Staff Position EITF 03-6-1,                  
Determining Whether Instruments Granted in Share-Based Payment                  
Transactions Are Participating Securities, ("FSP EITF 03-6-1"). FSP             
EITF 03-6-1 addresses whether instruments granted in share-based                
payment transactions are participating securities prior to vesting, and         
therefore need to be included in the computation of earnings per share          
under the two-class method as described in FASB Statement of Financial          
Accounting Standards No. 128, "Earnings per Share." FSP EITF 03-6-1 is          
effective for financial statements issued for fiscal years beginning on         
or after December 15, 2008 and earlier adoption is prohibited. We are           
not required to adopt FSP EITF 03-6-1; neither do we believe that FSP           
EITF 03-6-1 would have material effect on our consolidated financial            
position and results of operations if adopted.                                  

In May 2008, the Financial Accounting Standards Board ("FASB") issued           
SFAS No. 163, "Accounting for Financial Guarantee Insurance Contracts-          
and interpretation of FASB Statement No. 60".  SFAS No. 163 clarifies           
how Statement 60 applies to financial guarantee insurance contracts,            
including the recognition and measurement of premium revenue and claims         
liabilities. This statement also requires expanded disclosures about            
financial guarantee insurance contracts. SFAS No. 163 is effective for          
fiscal years beginning on or after December 15, 2008, and interim               
periods within those years. SFAS No. 163 has no effect on the Company's         
financial position, statements of operations, or cash flows at this             
time.                                                                           

F-15  

10-12G
47th Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 47th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 8.   Recent Pronouncements (Continued)                                     

In May 2008, the Financial Accounting Standards Board ("FASB") issued           
SFAS No. 162, "The Hierarchy of Generally Accepted Accounting                   
Principles".  SFAS No. 162 sets forth the level of authority to a given         
accounting pronouncement or document by category. Where there might be          
conflicting guidance between two categories, the more authoritative             
category will prevail. SFAS No. 162 will become effective 60 days after         
the SEC approves the PCAOB's amendments to AU Section 411 of the AICPA          
Professional Standards. SFAS No. 162 has no effect on the Company's             
financial position, statements of operations, or cash flows at this             
time.                                                                           

In March 2008, the Financial Accounting Standards Board, or FASB,               
issued SFAS No. 161, Disclosures about Derivative Instruments and               
Hedging Activities-an amendment of FASB Statement No. 133.  This                
standard requires companies to provide enhanced disclosures about (a)           
how and why an entity uses derivative instruments, (b) how derivative           
instruments and related hedged items are accounted for under Statement          
133 and its related interpretations, and (c) how derivative instruments         
and related hedged items affect an entity's financial position,                 
financial performance, and cash flows. This Statement is effective for          
financial statements issued for fiscal years and interim periods                
beginning after November 15, 2008, with early application encouraged.           
The Company has not yet adopted the provisions of SFAS No. 161, but             
does not expect it to have a material impact on its consolidated                
financial position, results of operations or cash flows.                        

In December 2007, the SEC issued Staff Accounting Bulletin (SAB) No.            
110 regarding the use of a "simplified" method, as discussed in SAB No.         
107 (SAB 107), in developing an estimate of expected term of "plain             
vanilla" share options in accordance with SFAS No. 123 (R), Share-Based         
Payment.  In particular, the staff indicated in SAB 107 that it will            
accept a company's election to use the simplified method, regardless of         
whether the company has sufficient information to make more refined             
estimates of expected term. At the time SAB 107 was issued, the staff           
believed that more detailed external information about employee                 
exercise behavior (e.g., employee exercise patterns by industry and/or          
other categories of companies) would, over time, become readily                 
available to companies. Therefore, the staff stated in SAB 107 that it          
would not expect a company to use the simplified method for share               
option grants after December 31, 2007. The staff understands that such          
detailed information about employee exercise behavior may not be widely         
available by December 31, 2007. Accordingly, the staff will continue to         
accept, under certain circumstances, the use of the simplified method beyond    
December 31, 2007. The Company currently uses the simplified method for         

F-16  

10-12G
Last Page of 48
TOC
1st
Previous
Next
↓Bottom
Just 48th
EZJR, Inc.
 (A Development Stage Company)
 Notes to Financial Statements
June 30, 2009 

NOTE 8.   Recent Pronouncements (Continued)                                     

"plain vanilla" share options and warrants, and will assess the impact of       
SAB 110 for fiscal year 2009. It is not believed that this will have an         
impact on the Company's consolidated financial position, results of             
operations or cash flows.                                                       

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in     
Consolidated Financial Statements-an amendment of ARB No. 51.  This statement   
amends ARB 51 to establish accounting and reporting standards for the           
noncontrolling interest in a subsidiary and for the deconsolidation of a        
subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an   
ownership interest in the consolidated entity that should be reported as        
equity in the consolidated financial statements. Before this statement was      
issued, limited guidance existed for reporting noncontrolling interests. As a   
result, considerable diversity in practice existed. So-called minority          
interests were reported in the consolidated statement of financial position     
as liabilities or in the mezzanine section between liabilities and equity.      
This statement improves comparability by eliminating that diversity. This       
statement is effective for fiscal years, and interim periods within those       
fiscal years, beginning on or after December 15, 2008 (that is, January 1,      
2009, for entities with calendar year-ends). Earlier adoption is prohibited.    
The effective date of this statement is the same as that of the related         
Statement 141 (revised 2007). The Company will adopt this Statement beginning   
March 1, 2009. It is not believed that this will have an impact on the          
Company's consolidated financial position, results of operations or cash        
flows.                                                                          

In December 2007, the FASB, issued FAS No. 141 (revised 2007), Business         
Combinations'.  This Statement replaces FASB Statement No. 141, Business        
Combinations, but retains the fundamental requirements in Statement 141.        
This Statement establishes principles and requirements for how the acquirer:    
(a) recognizes and measures in its financial statements the identifiable        
assets acquired, the liabilities assumed, and any noncontrolling interest in    
the acquiree; (b) recognizes and measures the goodwill acquired in the          
business combination or a gain from a bargain purchase; and (c) determines      
what information to disclose to enable users of the financial statements to     
evaluate the nature and financial effects of the business combination. This     
statement applies prospectively to business combinations for which the          
acquisition date is on or after the beginning of the first annual reporting     
period beginning on or after December 15, 2008. An entity may not apply it      
before that date. The effective date of this statement is the same as that of   
the related FASB Statement No. 160, Noncontrolling Interests in Consolidated    
Financial Statements.  The Company will adopt this statement beginning March    
1, 2009. It is not believed that this will have an impact on the Company's      
consolidated financial position, results of operations or cash flows.           

F-17

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘10-12G’ Filing		Date		First		Last			Other Filings
		3/1/10		46
		12/15/09		45
		11/15/09		42
Filed on:		10/15/09
		10/13/09		22		31			10-K
		10/10/09		32
		10/6/09		27
		9/15/09		43
		7/1/09		43
		6/30/09		9		48			10-K,  NT 10-K
		6/22/09		27
		6/15/09		44		45
		3/1/09		48
		1/1/09		44		48
		12/15/08		45		48
		11/15/08		47
		9/23/08		27
		7/25/08		3		30			3,  8-K,  8-K/A
		6/30/08		26		36			10-K
		4/14/08		30					10KSB
		3/31/08		39					10QSB,  NT 10-K
		12/31/07		47					10KSB,  10KSB/A,  NT 10-K
		6/30/07		28		35			10QSB
		3/15/07		4		30
		11/1/06		38		40
		8/14/06		3		38
		12/30/05		21
		2/2/02		38
		2/2/00		11
									List all Filings